Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced BRAF-mutant Cancers”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Ended earlyNCT01616199
What this trial is testing

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Who this might be right for
Advanced BRAF-mutant Cancers
Cascadian Therapeutics Inc. 24
Testing effectiveness (Phase 2)Ended earlyNCT01777776
What this trial is testing

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Who this might be right for
Locally Advanced Metastatic BRAF Mutant Melanoma
Array BioPharma 28
Large-scale testing (Phase 3)WithdrawnNCT02427893
What this trial is testing

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Who this might be right for
Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Early research (Phase 1)Study completedNCT01436656
What this trial is testing

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Who this might be right for
Melanoma and Metastatic Colorectal Cancer
Pfizer 107
Testing effectiveness (Phase 2)Study completedNCT02296996
What this trial is testing

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Who this might be right for
Malignant Melanoma
Universitair Ziekenhuis Brussel 25
Early research (Phase 1)Study completedNCT03415126
What this trial is testing

ASN007 in Patients With Advanced Solid Tumors

Who this might be right for
CancerMalignancyNeoplasia+16 more
Asana BioSciences 49
Large-scale testing (Phase 3)Study completedNCT01227889
What this trial is testing

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Who this might be right for
Cancer
GlaxoSmithKline 251
Early research (Phase 1)Ended earlyNCT02974725
What this trial is testing

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Who this might be right for
Non-Small Cell Lung CancerMelanoma
Novartis Pharmaceuticals 241
Large-scale testing (Phase 3)Study completedNCT01245062
What this trial is testing

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline 322
Early research (Phase 1)Study completedNCT03864042
What this trial is testing

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Melanoma
Pfizer 56
Testing effectiveness (Phase 2)UnknownNCT04653480
What this trial is testing

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

Who this might be right for
Colorectal Cancer
Zhejiang University 61
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Early research (Phase 1)Study completedNCT05003622
What this trial is testing

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Who this might be right for
BRAF V600E Unresectable or Metastatic MelanomaBRAF V600E Metastatic NSCLCMelanoma
Pierre Fabre Medicament 3
Testing effectiveness (Phase 2)WithdrawnNCT03972046
What this trial is testing

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Who this might be right for
Melanoma (Skin)Melanoma Stage IIIb-IVM1aMetastasis Skin+2 more
TriHealth Inc.
Testing effectiveness (Phase 2)Study completedNCT01320085
What this trial is testing

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Who this might be right for
BRAF or NRAS Mutant Metastatic Melanoma
Pfizer 183
Testing effectiveness (Phase 2)Ended earlyNCT01519427
What this trial is testing

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Who this might be right for
Recurrent MelanomaStage IIIA MelanomaStage IIIB Melanoma+2 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Study completedNCT03843775
What this trial is testing

Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Who this might be right for
Advanced BRAF Mutant Cancers
Memorial Sloan Kettering Cancer Center 17
Early research (Phase 1)Study completedNCT01897116
What this trial is testing

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Who this might be right for
Melanoma
Abramson Cancer Center at Penn Medicine 8
Early research (Phase 1)Ended earlyNCT05501912
What this trial is testing

ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorBRAF V600 Mutation
ABM Therapeutics Shanghai Company Limited 20
Testing effectiveness (Phase 2)Study completedNCT01512251
What this trial is testing

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Who this might be right for
BRAF Mutant Metastatic Melanoma
University of California, San Francisco 8
Load More Results